Nika Pharmaceuticals Completes Asset Acquisition/Disposition

Ticker: NIKA · Form: 8-K · Filed: May 10, 2024 · CIK: 1145604

Nika Pharmaceuticals, Inc 8-K Filing Summary
FieldDetail
CompanyNika Pharmaceuticals, Inc (NIKA)
Form Type8-K
Filed DateMay 10, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$957,670, $191,534
Sentimentneutral

Sentiment: neutral

Topics: acquisition, disposition, corporate-action

TL;DR

Nika Pharma closed an asset deal on 4/23, filing 8-K on 5/10.

AI Summary

Nika Pharmaceuticals, Inc. (formerly Centennial Growth Equities Inc.) filed an 8-K on May 10, 2024, reporting on the completion of an acquisition or disposition of assets as of April 23, 2024. The filing also includes other events and financial statements/exhibits.

Why It Matters

This filing indicates a significant corporate action, likely involving the acquisition or sale of assets, which could impact Nika Pharmaceuticals' business operations and financial structure.

Risk Assessment

Risk Level: medium — Acquisitions and dispositions of assets can introduce significant financial and operational risks.

Key Numbers

  • 000-56234 — SEC File Number (Identifies the company's filing with the SEC.)
  • 90-0292940 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

  • NIKA PHARMACEUTICALS, INC. (company) — Registrant
  • CENTENNIAL GROWTH EQUITIES INC (company) — Former company name
  • 20240510 (date) — Filing date
  • 20240423 (date) — Date of earliest event reported
  • 7023263615 (phone_number) — Registrant's telephone number

FAQ

What specific assets were acquired or disposed of by Nika Pharmaceuticals, Inc. on April 23, 2024?

The filing indicates the completion of an acquisition or disposition of assets on April 23, 2024, but does not specify the exact assets involved in this section.

What is the nature of the 'Other Events' reported in this 8-K filing?

The filing mentions 'Other Events' as a category but does not provide details on what these events entail within the provided text.

When was Nika Pharmaceuticals, Inc. formerly known as Centennial Growth Equities Inc.?

The date of the name change from Centennial Growth Equities Inc. to Nika Pharmaceuticals, Inc. was July 24, 2001.

What is the principal executive office address for Nika Pharmaceuticals, Inc.?

The principal executive offices are located at 2269 Merrimack Valley Avenue, Henderson, NV 89044.

What is the SIC code for Nika Pharmaceuticals, Inc.?

The Standard Industrial Classification (SIC) code for Nika Pharmaceuticals, Inc. is 3790, categorized under Miscellaneous Transportation Equipment.

Filing Stats: 574 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-05-10 12:47:52

Key Financial Figures

  • $957,670 — uring Practice (GMP) standards, costing $957,670. Dimitar Savov has paid the initial dow
  • $191,534 — ov has paid the initial down payment of $191,534 from his personal money. The equipment

Filing Documents

01 Completion of Acquisition of Assets

Item 2.01 Completion of Acquisition of Assets. Effective May 9, 2024, Nika Pharmaceuticals, Inc. acquired 100% of Nika Pharmaceuticals, Ltd., a limited liability company registered in Bulgaria with UIC: 175420503. The ownership was acquired from Dimitar SlavchevSavov who is an officer, director and majority shareholder of Nika Pharmaceuticals, Inc. and general manager of Nika Pharmaceuticals, Ltd. for the nominal value of the capital of the company, 5,000 BGN. Nika Pharmaceuticals, Ltd.s Actual State Certificate and Certificate of Registered Entriesare furnished below as Exhibits20.1 and 20.2 respectively. With this acquisition, Nika Pharmaceuticals, Inc. becomes the Pharmaceuticals, Ltd. made a non-monetary in-kind contribution of a production building and land to the capital of Nika Europe, Ltd. The building and land were officially valued at 3,683,800 BGN (2,045,209) USD by three independent evaluators appointed by the Bulgarian Registry Agency. A certified translation of the expertise for the valuation of the contribution in kind is furnished below as Exhibit 20.3. Simply put, with the May 9, 2024 acquisition of Nika Pharmaceuticals, Ltd., Nika Pharmaceuticals, Inc. becomes the beneficial owner of a factory building and landvalued at 2,045,209 USD, situated in a strategic location in Sofia province, which were originally purchased and renovated by Dimitar Savov at his own personal expense. Section 8 - Other Events

01 Other Events

Item 8.01 Other Events. On April 23, 2024, Nika Europe, Ltd. signed a Supply Agreement with Shanghai Marya Pharmaceutical Engineering & Project Co., Ltd. for the purchase, supply, and installation of a complete vial production line equipment adhering to Good Manufacturing Practice (GMP) standards, costing $957,670. Dimitar Savov has paid the initial down payment of $191,534 from his personal money. The equipment is scheduled to be produced, delivered, and installed in the Bulgarian production building by the end of Q4, 2024.

01 Exhibits

Item 9.01 Exhibits (d) Exhibits EX20.1 Nika Pharmaceuticals, Ltd. May 9, 2024 Actual State Certificate EX20.2 Nika Pharmaceuticals, Ltd. May 9, 2024 Certificate of Registered Entries EX20.3 Nika Europe Ltd. Expertise for the Valuation of In-kind Contribution

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized. NIKA PHARMACEUTICALS, INC. Dated: May 10, 2024 By: /s/ Dimitar SlavchevSavov Dimitar SlavchevSavov Chief Executive Officer, Director

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.